| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
Ligands in Uterine Leiomyoma1
University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957 [K. D. H., S. M. F., C. L. W.]; Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555 [J. A. C.]; Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [R. R. B.]; and Bristol-Myers Squibb, Endocrine Oncology Pharmaceutical Research Institute, Princeton, New Jersey 08543 [M. M. G.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
is an important signaling molecule in cells of mesenchymal origin, inducing differentiation and regulating cell proliferation in several cell types such as vascular smooth muscle cells. Leiomyomas arise from smooth muscle cells of the uterine myometrium with an incidence rate as high as 70% in women of reproductive age. PPAR signaling has not been characterized in these tumors, although prostaglandins, natural PPAR ligands, are known effectors of key biological functions in the normal myometrium. Leiomyomas and tumor-derived cells isolated from a rat model for this disease were characterized by Western analysis and found to express all three PPAR isoforms, suggesting that signaling pathways mediated by these receptors were intact in this tumor type. In vitro experiments with a leiomyoma-derived cell line demonstrated that the pan-PPAR ligand cis-4,7,10,13,16,19-docosahexaenoic acid and PPAR-specific ligands 15-deoxy-
12,14-prostaglandin J2, troglitazone, and ciglitazone inhibited 17ß-estradiol-stimulated cell proliferation. This inhibitory effect was not observed with PPAR
- or PPARß-specific ligands. Although both PPAR and estrogen receptor (ER) signaling pathways were intact in leiomyoma cells, in addition to growth inhibition, stimulation of PPAR signaling also inhibited ER-mediated gene expression. Human leiomyomas were also found to express all three PPAR isoforms, and primary cultures of these cells were sensitive to the inhibitory effects of PPAR ligands. These results suggest that in uterine leiomyomas PPAR activation is growth inhibitory and that this inhibition is mediated at least in part by negative cross-talk between ER and PPAR signaling pathways. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, ß/
, and , has been described in multiple species. Whereas PPARß/ is ubiquitously expressed, PPARs and are expressed in a tissue-specific manner (1)
. After ligand binding, PPARs heterodimerize with the ligand-bound RXR (2)
and modulate gene expression via binding to a specific DNA-regulatory element called the PPRE. The tissue-specific expression of PPARs suggests that these receptors are involved in a variety of specialized biological functions.
PPAR was the first PPAR identified (3)
and is highly expressed in the liver, kidney, and heart of the adult rat (1)
. This isoform modulates the transcription of genes encoding enzymes involved in fatty acid oxidation (4
, 5)
, as well as apolipoproteins that function to control cholesterol levels in serum (6)
. The ubiquitous PPARß/ is expressed at higher levels than PPAR or PPAR in most tissues, although much less is known about the biological function of this isoform. PPAR plays an important role in adipocyte differentiation and has been described in both humans and rodents. Furthermore, PPAR ligands have been shown to inhibit proliferation and/or induce apoptosis in many cell types (7, 8, 9)
. The two variants of this isoform, PPAR1 and PPAR2, are derived from distinct transcription start sites and result from alternative splicing during transcription. Although there is no evidence supporting a functional difference between the PPAR variants, the relative expression of these variants is not equal in all tissues. PPAR1 seems to be ubiquitously expressed, whereas higher levels of PPAR2 are expressed in adipose tissue (10
, 11)
.
Uterine leiomyomas, or "fibroids," are benign smooth muscle tumors originating from the myometrium. These tumors have a reported incidence of as high as 77% in women of reproductive age and are the leading indication for hysterectomy in the United States (12 , 13) . Common symptoms associated with these tumors are dysmenorrhea, menorrhagia, infertility, and morbidity (12) . In the majority of cases, alterations in hormonal milieu appear to underlie the impact of risk factors associated with fibroid development (14, 15, 16, 17, 18) . The growth of uterine leiomyoma is thought to be modulated by the ovarian hormones, estrogen (E2) and progesterone. Hormone-dependent leiomyoma growth is evidenced by the fact that most of these tumors are diagnosed during the reproductive years, change in size during pregnancy, and regress after the onset of menopause (12) , events coinciding with changes in hormonal milieu. Furthermore, treatment with gonadotropin-releasing hormone agonists, which interfere with signaling pathways of the hypothalamic-pituitary axis, halts or reverses uterine leiomyoma growth through induction of a hypoestrogenic state (19 , 20) .
The Eker rat is a well-characterized animal model for spontaneous uterine leiomyoma (21
, 22)
. Heterozygous (Tsc2EK/+) female Eker rats carrying a germ-line mutation of the tuberous sclerosis (Tsc2) tumor suppressor gene develop grossly observable tumors with an incidence of approximately 65% by 12–16 months of age (23)
. Eker rat leiomyomas are histologically similar to human leiomyomas and express the smooth muscle markers desmin and smooth muscle -actin (21)
. An Eker leiomyoma tumor-derived cell line (ELT-3) was characterized with respect to ER and PR expression (24)
and has been successfully used in many studies to investigate the hormonal modulation of leiomyomas (25, 26, 27)
.
The role of PPAR signaling in leiomyoma cells has not been elucidated to date. In the present study, PPAR expression was characterized in normal and neoplastic myometrial tissues, and the ability of PPAR ligands to inhibit the proliferation of leiomyoma cells was determined. These preclinical data demonstrated that treatment of leiomyoma cells with PPAR ligands specifically inhibited E2-dependent proliferation and gene expression, demonstrating cross-talk between these two signaling pathways in these tumors and suggesting that PPAR ligands may have clinical relevance for the treatment of uterine leiomyoma.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Chemical Compounds.
Tro was a gift from M. M. Gottardis (Bristol Myers-Squibb, Princeton, NJ) or a gift from Sankyo Company Ltd. (Tokyo, Japan). BMS-263990-01-001 was a gift from M. M. Gottardis (Bristol Myers-Squibb), and 15PGJ2 was purchased from BIOMOL Research Labs Inc. (Plymouth Meeting, PA) or Cayman Chemical Co. (Ann Arbor, MI). Cig and Wy-14643 were purchased from BIOMOL Research Labs Inc. Ros was a gift from Sankyo Company Ltd. Bez, E2, DMSO, and ethanol were purchased from Sigma Chemical Co.
Cell Growth Kinetics.
ELT-3 cells were plated at 5000 cells/well in 24-well plates and grown for 48 h in DF8 media containing 10% FBS. Cells were counted and then treated on day 0 in E2-free media with vehicle, E2, PPAR ligand and vehicle, or PPAR ligand and E2. In the instance where dual treatments were administered, two vehicle controls were used. Cells were washed once with 1x PBS and then collected using 3x trypsin and counted on days 3, 5, 6, and 7 (if possible) using a Coulter Z1 counter (Coulter Electronics, Hialeah, FL).
Rat Tissues.
Eker rats were maintained on a 14-h light/10-h dark cycle, with food and water provided ad libitum. Eker rats between the ages of 12 and 16 months were sacrificed by CO2 asphyxiation. Normal myometrial tissue pooled from 12–16-month-old animals was obtained after removing the endometrial lining of the uterus by scraping using a sterile scalpel, followed by PBS rinse; snap-frozen in liquid N2; and then stored at -80°C. Leiomyomas collected from tumor-bearing animals were snap-frozen and stored at -80°C. Rats were maintained and handled according to NIH guidelines and in Association for the Accreditation of Laboratory Animal Care-accredited facilities. The protocols involving use of these animals were approved by the MD Anderson Cancer Center Institutional Animal Care and Use Committee.
Human Tissues.
Leiomyoma and normal myometrium were collected from surgical hysterectomy specimens submitted to the Department of Pathology, University of Texas M. D. Anderson Cancer Center. Both leiomyoma and normal myometrium were snap-frozen in liquid nitrogen and stored at -80°C.
Western Blots.
All tumor and normal myometrium samples were pulverized using mortar and pestle in liquid N2 and then immediately transferred to radioimmunoprecipitation assay buffer containing protease inhibitors (leupeptin, phenylmethylsulfonyl fluoride, and aprotinin) and incubated for 1 h at 4°C. After a 10-min spin at 10,000 x g, the supernatant containing the total cell lysate was quantitated using BCA Protein Assay Reagent (Pierce, Rockford, IL). Thirty µg (or 15 µg for LM2 cells) of total cell lysate were resolved by SDS-PAGE using a 4–20% gradient or 7.5% gel (Bio-Rad Laboratories, Hercules, CA) or 10% gel. Proteins were transferred overnight to polyvinylidene difluoride membrane and blocked for 1–2 h in 5% milk TBST or 2% milk PBST. A 1:1000 dilution of primary antibodies recognizing PPAR, PPARß (Affinity Bioreagents, Denver, CO), PPAR, ER, -tubulin, and ß-actin [1:6000 (Santa Cruz Biotechnology, Santa Cruz, CA)] or PR (Calbiochem, La Jolla, CA) was hybridized in 1% milk TBST for 2 h or in 4% milk PBST for 2 h. The membranes were then washed once with Tris-buffered saline, followed by three washes with TBST and one final wash with Tris-buffered saline each for 5’. PPAR antibody recognized Mr 56,000 and Mr 52,000 variants that correspond to PPAR1 and PPAR2. Antirabbit or antimouse IgG secondary antibody conjugated to horseradish peroxidase (Santa Cruz Biotechnology) was hybridized for 1 h in 1% milk TBST. The wash sequence was the same as that stated previously. Whole cell lysates from rat liver were used as positive controls for Western analysis of PPAR isoforms. All hybridizations and washes were performed at room temperature. LumiGLO (KPL, Gaithersburg, MD) was used for visualization. Consistent protein amounts were determined by staining the membrane after hybridization with Ponceau S (Sigma Chemical Co.), and -tubulin or ß-actin expression was used to assess consistent loading between samples. PR-A expression was quantitated densitometrically and normalized using -tubulin expression.
Reporter Gene Assays.
ELT-3 cells were plated at 15,000 cells/well in 12-well plates and grown for 24 h in DF8 media containing 10% FBS. Effectene Transfectant Reagent kit (Qiagen, Valencia, CA) was used to transfect cells with pCMV-ß-galactosidase (a gift from Dr. A. Butler; University of Texas M. D. Anderson Cancer Center) and vit-ERE-Luc plasmids (28)
. Cells were washed twice with 1x PBS and then treated with increasing doses of PPAR ligand for 24 h, followed by treatment with vehicle or E2 for 24 h. At that time, luminescence and ß-galactosidase values were determined using the Promega Luciferase Assay System (Madison, WI) and Tropix Galactolight (Bedford, MA) according to the manufacturer’s instructions. Luminescence was detected using a Dynex-MLX Luminometer (Chantilly, VA). Luciferase activity was normalized with ß-galactosidase values to correct for transfection efficiency. Cells were plated at 100,000 cells/60-mm plate in DMEM containing 5% FBS and transfected the following day with 2 µg of PPRE-luc plasmid (a gift from Dr. R. Evans) and 0.1 ng of Renilla luciferase plasmid (Promega) using FuGene transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN) at a ratio of 1 µg DNA:3 µl FuGene. On the following day, cells were treated with either a 1:1,000 dilution of DMSO or an appropriate concentration of PPAR ligand. Twenty-four h later, cells were lysed, and firefly luciferase and Renilla luciferase activities were measured in a Lumat luminometer.
Cell Proliferation Assay.
A fluorometric assay, implementing Hoechst 33258 (bisbenzimide), was used for DNA quantitation. LM2 cells (25,000 cells/well) were plated on a 12-well plate in 1 ml of DMEM media supplemented with FBS and penicillin-streptomycin-antimycotic (described above). The cells were allowed to attach overnight at 37°C, and then the media were replaced with media containing the appropriate treatment of 15PGJ2, Tro, or Ros. Control cells were treated with a 1:1,000 dilution of DMSO. The cells were incubated for 3 days, followed by cell lysis and DNA content determination using Hoechst dye solution (10 µl/100 ml distilled H2O). Fluorescence was measured (DyNA Quant 200; Hoefer Pharmacia Biotech) after excitation at 365 nm and fluorescence at 458 nm. Calf thymus DNA (Sigma) was used as a standard to determine DNA concentration. Antisense and sense phosphorothioate-modified oligodeoxynucleotides were designed using the PPAR nucleotide cDNA sequence. The PPAR antisense (5'-CTC-TGT-GTC-AAC-CAT-GGT-CAT-3') and sense (5'-ATG-ACC-ATG-GTT-GAC-ACA-GAG-3') oligonucleotides were provided by Sigma-Genosys (Woodlands, TX). Cells were plated as described above and treated daily with either sense or antisense oligonucleotides at a final concentration of 10 µM. On the second day of treatment with oligonucleotide, cells were treated with PPAR agonists and then allowed to proliferate for 3 days. DNA content was then determined.
Statistical Analysis.
Statview 5.01 (SAS Institute, Cary, NC) was used for statistical calculations (ANOVA, means and SE).
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
.
|
Ligands Inhibit E2-induced Leiomyoma Cell Proliferation.
.
|
ligand 15PGJ2 significantly inhibited E2-induced proliferation of ELT-3 cells when treated with 5–20-µM doses (Fig. 2B)
. To confirm the effect of PPAR ligands on ELT-3 cell growth, the synthetic PPAR-activating thiazolidinediones, Tro and Cig, were also evaluated for the ability to inhibit E2-stimulated proliferation. Treatment of ELT-3 cells with Tro (Fig. 2C)
and Cig (data not shown) in the presence of E2 resulted in a decrease in ELT-3 cell number when compared with growth with E2 treatment alone. To determine whether growth inhibition mediated by PPAR was specific for PPAR-activating compounds, E2-stimulated cells were treated with 50–100 µM Wy-14643 (PPAR ligand) or 5–20 µM BMS-263990-01--001 (PPARß ligand). These compounds had no effect on ELT-3 cell number in the presence of E2 treatment at the tested doses (Fig. 2D)
. A 5-µM dose of the PPAR/ß ligand Bez (29)
significantly inhibited ELT-3 cell growth, whereas 10- and 20-µM doses did not inhibit the E2-stimulated growth of this cell type (Fig. 2D)
. These results indicate that PPAR-activating compounds, unlike PPAR- or PPARß-activating compounds, can inhibit the estrogen-dependent proliferation of leiomyoma cells.
Except for the highest dose of 15PGJ2, none of the above treatments with PPAR ligands significantly altered ELT-3 cell proliferation in E2-free media, as assessed by a decrease in ELT-3 cell number (data not shown). These data indicate that treatment with PPAR ligands specifically inhibits the E2-induced proliferation of ELT-3 cells and, with the exception of the highest dose of 15PGJ2, does not appear to have any overt toxicity.
PPAR Ligands Modulate ER Activity in ELT-3 Cells.
The ability of PPAR ligands to specifically inhibit E2-induced cell growth suggested that these compounds could modulate ER-mediated signaling. To confirm that this was the case, leiomyoma cells were transfected with a vit-ERE-Luc reporter plasmid and treated with E2 and vehicle or E2 and various PPAR ligands. Twenty-four-h pretreatment of ELT-3 cells with 15PGJ2 or Tro, compounds known to activate PPAR, inhibited the transactivation of a vit-ERE-Luc reporter gene in response to E2 in a dose-dependent manner (Fig. 3, A and B
, respectively). The PPAR/ß-activating compound Bez failed to inhibit E2-induced ERE transactivation in leiomyoma cells (Fig. 3C)
. Likewise, the PPAR-activating compound Wy-14643 did not inhibit E2-mediated transactivation of this reporter in leiomyoma cells (data not shown). Although Wy-14643 did not significantly inhibit transactivation of the reporter in the presence of E2 at 1–50-µM doses, there was a slight decrease in transactivation with a 50-µM dose (data not shown). Although it was not significant, this inhibition was reproducible.
|
PGJ2 pretreatment also inhibited the E2-dependent expression of PR-A, an endogenous target of ER transactivation (Fig. 4A
, top panel). Average data from three independent experiments revealed that 0.1-, 1-, and 10-µM doses of 15PGJ2 inhibited the expression of PR-A by 32%, 33%, and 57% respectively. Only the highest dose of 15PGJ2 significantly inhibited PR-A expression (Fig. 4B)
. Tro pretreatment also resulted in diminished PR-A expression in response to E2, but to a lesser extent than was observed after 15PGJ2 pretreatment (data not shown). One trivial explanation for diminished downstream ER activity is a decrease in ER expression after treatment with PPAR ligands. As shown by Western analysis, the levels of ER remained constant in ELT-3 cells regardless of treatment, indicating that the decrease in ER transactivation is not due to a decrease in ER in the cells after treatment with PPAR ligands (Fig. 4A
, bottom panel). These data demonstrate the ability of PPAR-specific ligands to interfere with the action of ER in response to E2 and suggest that negative cross-talk between ER and PPAR signaling pathways is a potential mechanism by which leiomyoma cell growth can be inhibited by PPAR ligands.
|
. PPAR expression varied in the leiomyoma samples compared with the matched myometrium; however, no consistent pattern could be determined.
|
Treatment Inhibits the Growth of Human Leiomyoma Cells. ligands to assess the ability of these compounds to initiate transcription in this cell type and determine the viability of these cells in response to treatment. As shown by relative luciferase values, compounds known to activate PPAR (15PGJ2, Tro, and Ros) enhanced the transcription of a luciferase reporter driven by a PPRE-containing promoter (Fig. 6)
. Treatment of LM2 cells with PPAR ligands 15PGJ2, Tro, and Ros resulted in diminished proliferation of this cell type compared with vehicle-treated cells (Fig. 7A)
. To determine whether this effect was PPAR dependent, LM2 cells were transfected with PPAR antisense oligonucleotides before treatment. The introduction of these oligonucleotides reversed the decrease in cell number observed in response to 15PGJ2, Tro, and Ros, suggesting that inhibition was PPAR dependent (Fig. 7B)
. The efficacy of the antisense oligonucleotide depletion of endogenous PPAR was confirmed by measuring PPAR protein levels by Western blot (Fig. 7C)
. These data suggest that, similar to results obtained in the Eker rat model, PPAR ligands inhibit proliferation of primary human leiomyoma cells in a PPAR-specific manner.
|
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
ligands in E2-responsive leiomyoma cells (rat) resulted in a significant decrease in cell number when compared with E2 treatment alone. PPAR and PPARß ligands had no inhibitory effect on proliferation in these cells. The ability of PPAR-activating compounds to inhibit leiomyoma cell proliferation was also confirmed in human primary leiomyoma cultures, although growth inhibition in these cells was not determined in estrogen-free conditions. Furthermore, an inhibition of E2-dependent ERE activation and a reduction in E2-induced PR levels were demonstrated in ELT-3 cells in response to PPAR ligands.
Previous studies have demonstrated that PPAR can modulate ERE transactivation. In an artificial promoter context, PPAR-RXR heterodimers can bind and transactivate an ERE-containing promoter (30)
. This transactivation was not achieved in the more natural, ERE-containing promoter of the PS2 gene. Negative PPAR-ER cross-talk demonstrated in this system was attributed to activated PPAR-RXR heterodimers physically blocking ER binding to the ERE of this promoter, thus inhibiting ER-mediated transcription of the associated reporter gene. Our data demonstrated PPAR ligand-mediated inhibition of ER-responsive gene transactivation and ER-induced protein expression. The mechanism of nuclear receptor cross-talk between PPAR and ER in leiomyoma responsible for this observation has not yet been determined. Interestingly, Tro has been shown to inhibit the growth of breast cancer cells, and ER-positive breast cancer cells are more sensitive to this inhibition (7)
. It will be important to further investigate the ability of PPARs to modulate the activity of steroid hormone receptors in these and other hormonally responsive cell types.
A possible tumor suppressor role for PPAR has been previously postulated for colon carcinoma; approximately 7% of human colon carcinomas tested (4 of 55) had loss of function mutations in PPAR (31)
. Furthermore, the growth of transplanted colon cancer cells in nude mice was significantly inhibited when treated with Tro (8)
. In contrast to a previous study of PPARs in leiomyoma that indicated that PPAR levels were increased in human leiomyomas (32)
, no increased PPAR expression was observed in rat or human leiomyoma samples relative to matched myometrium. The size of the immunoreactive band ascribed to PPAR2 (Mr >60,000) in that study differed significantly from the Mr 
52,000 (PPAR1) and Mr 56,000 (PPAR2) bands recognized in our study and reported by other investigators (33
, 34)
. Consistent with our observation that PPAR expression is unchanged in leiomyoma compared with matched myometrium, PPAR message levels were previously reported to be the same in human leiomyomas compared with adjacent myometrium (35)
. Furthermore, Tro treatment prevented the formation of abdominal leiomyoma induced by E2 in hormone-treated guinea pigs (32)
. These data suggest that Tro had a protective effect on the development of uterine leiomyoma in the guinea pig, findings consistent with a growth-inhibitory role for PPAR in leiomyoma. Clearly, much more work needs to be focused on understanding the involvement of PPARs in this tissue and the possible role of these receptors as ER modulators.
The regulation of leiomyoma growth by ovarian steroid hormones has been well described (12
, 19
, 20)
. Similar to human leiomyomas, the ELT-3 leiomyoma cells retain expression of ER and PR as well as the ability to respond to steroid hormones (24, 25, 26, 27)
. This differs from human leiomyoma cell cultures, which have been reported to undergo a 75% decrease in ER and PR expression within 8 h of culture (36)
, and these cultures consistently lose hormone responsiveness (37)
. Therefore, ELT-3 cells are a unique, in vitro tool to study the effects of steroid hormones on leiomyoma growth and evaluate steroid receptor signaling mechanisms. In this study, we used the ELT-3 cells to demonstrate that PPAR ligands exhibited transdominant suppression of ER action in leiomyoma cells, inhibiting proliferation and ER signaling response to steroid hormones. To date, this is the first report suggesting that nuclear receptor cross-talk is a mechanism by which PPAR ligands may exert antiproliferative effects. Although the ability of activated PPAR to interfere with ER action will continue to be explored, these data provide evidence for PPAR-ER cross-talk and suggest that PPAR ligands should be examined as candidate therapeutic agents for uterine leiomyoma.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported in part by NIH Grants ES08263, ES07784, and 2T32 CA09480. 
2 To whom requests for reprints should be addressed, at University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, Box 389, Smithville, TX 78957. Phone: (512) 237-9550; Fax: (512) 237-2475.
3 The abbreviations used are: PPAR, peroxisome proliferator-activated receptor; ER, estrogen receptor; PR, progesterone receptor; E2, 17ß-estradiol; DHA, cis-4,7,10,13,16,19-docosahexaenoic acid; Tro, troglitazone; Cig, ciglitazone; Bez, Bezafibrate; 15PGJ2, 15-deoxy-12,14-prostaglandin J2; Ros, rosiglitazone; PPRE, peroxisome proliferator response element; RXR, retinoid X receptor; FBS, fetal bovine serum; ERE, estrogen response element; TBS, tris buffered saline; TBST, TBS containing 0.5% Tween 20; PBST, phosphate buffered saline containing 0.5% Tween 20.
Received 8/22/02. Accepted 11/13/02.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, -ß, and - in the adult rat. Endocrinology, 137: 354-366, 1996.[Abstract]
and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA, 95: 8806-8811, 1998.. Nat. Med., 4: 1046-1052, 1998.[Medline]
(troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res., 58: 3344-3352, 1998. gene. J. Biol. Chem., 272: 18779-18789, 1997. (mPPAR ) gene: alternative promoter use and different splicing yield two mPPAR isoforms. Proc. Natl. Acad. Sci. USA, 92: 7921-7925, 1995. associated with human colon cancer. Mol. Cell, 3: 799-804, 1999.[Medline]
, retinoid X receptor , and all-trans-retinoic acid than myometrium. Cancer Res., 59: 5737-5744, 1999.. Science (Wash. DC), 274: 2100-2103, 1996. in rat and human vascular smooth muscle cells. Circulation, 101: 1311-1318, 2000.This article has been cited by other articles:
|
|
 |
|
  A. Isobe, T. Takeda, M. Sakata, A. Miyake, T. Yamamoto, R. Minekawa, F. Nishimoto, Y. Oskamoto, C. L. Walker, and T. Kimura Dual repressive effect of angiotensin II-type 1 receptor blocker telmisartan on angiotensin II-induced and estradiol-induced uterine leiomyoma cell proliferation Hum. Reprod., February 1, 2008; 23(2): 440 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-H. Nam, S. Ramachandran, D.-K. Song, K.-Y. Kwon, D.-S. Jeon, S.-J. Shin, S.-H. Kwon, S.-D. Cha, I. Bae, and C.-H. Cho Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR gamma ligand ciglitizone Mol. Hum. Reprod., November 1, 2007; 13(11): 829 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takemura, Y. Osuga, O. Yoshino, A. Hasegawa, T. Hirata, Y. Hirota, E. Nose, C. Morimoto, M. Harada, K. Koga, et al. Metformin Suppresses Interleukin (IL)-1{beta}-Induced IL-8 Production, Aromatase Activation, and Proliferation of Endometriotic Stromal Cells J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3213 - 3218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kiyomizu, J. Kitawaki, H. Obayashi, M. Ohta, H. Koshiba, H. Ishihara, and H. Honjo Association of Two Polymorphisms in the Peroxisome Proliferator-Acativated Receptor-{gamma} Gene With Adenomyosis, Endometriosis, and Leiomyomata in Japanese Women Reproductive Sciences, July 1, 2006; 13(5): 372 - 377. [Abstract] [PDF]
|
|
|
|
|
|
F. Demirturk, H. Aytan, A. C. Caliskan, P. Aytan, and D. R. Koseoglu Effect of Peroxisome Proliferator--Activated Receptor-{gamma} Agonist Rosiglitazone on the Induction of Endometriosis in an Experimental Rat Model Reproductive Sciences, January 1, 2006; 13(1): 58 - 62. [Abstract] [PDF]
|
|
|
|
 |
|
 S. E. Bulun, Z. Lin, G. Imir, S. Amin, M. Demura, B. Yilmaz, R. Martin, H. Utsunomiya, S. Thung, B. Gurates, et al. Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment Pharmacol. Rev., September 1, 2005; 57(3): 359 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.J. Loy, S. Evelyn, F.K. Lim, M.H. Liu, and E.L. Yong Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-{gamma} ligand, pioglitazone Mol. Hum. Reprod., August 1, 2005; 11(8): 561 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sandelin and W. W. Wasserman Prediction of Nuclear Hormone Receptor Response Elements Mol. Endocrinol., March 1, 2005; 19(3): 595 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Y. Kim, C.-H. Cho, D.-K. Song, K.-C. Mun, S.-I. Suh, S.-P. Kim, D.-H. Shin, B.-C. Jang, T. K. Kwon, S.-D. Cha, et al. Ciglitizone inhibits cell proliferation in human uterine leiomyoma via activation of store-operated Ca2+ channels Am J Physiol Cell Physiol, February 1, 2005; 288(2): C389 - C395. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal |
